In line with the CD27 crosslinking requirements, previous studies with syngeneic mouse tumor models have shown that Varlilumab induces FcR-engagement-dependent tumor regression and facilitates long-term anti-tumor immunity (13). The gene discussed is CD27; the disease is neoplasm.